VT Bio "Obtains MFDS Approval for 'Bronpass Tablets' Based on VT014 for Lung Disease Treatment"

[Asia Economy Reporter Jang Hyowon] VT GMP's affiliate VT Bio announced on the 16th that it received notification from Hallim Pharmaceutical that 'Bronpass Tablets,' a drug based on the chronic obstructive pulmonary disease treatment 'VT014,' has obtained product approval from the Ministry of Food and Drug Safety.

Bronpass Tablets mainly consist of Rehmannia glutinosa, Moutan Cortex, Schisandra, Asparagus cochinchinensis, Scutellaria baicalensis, Armeniacae Semen, White Peony Root Soft Extract, and Corn Starch Mixed Dry Powder. It is a natural product new drug that received product approval nine years after the approval of Yutuma External Solution in 2012. VT Bio licensed the chronic obstructive pulmonary disease treatment VT014 (formerly PM014) to Hallim Pharmaceutical in 2011 and also went through an indication change process for acute bronchitis.

Acute bronchitis is a disease in which pathogens such as viruses and bacteria invade the airways and trachea from the throat to the lungs, causing an acute inflammatory response. When influenza, such as epidemic flu, spreads, the incidence of acute bronchitis also increases.

In addition to VT014, VT Bio plans to focus on licensing natural product new drug pipelines such as VT011 (formerly PM011, antidepressant) and VT012 (formerly PM012, dementia treatment), which have undergone clinical trials.